Immunosuppression following heart transplantation: Prospects and challenges

Immunotherapy

Volumn 6, Issue 2, 2014, Pages 181-194

  Chang, David H ^a   Kittleson, Michelle M ^a   Kobashigawa, Jon A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

antibody sensitization; antibody mediated rejection; cardiac allograft vasculopathy; cellular rejection; heart transplant; immunosuppression; induction therapy

Indexed keywords

ANIMALS; ANTIMETABOLITES; CALCINEURIN; GRAFT REJECTION; GROWTH INHIBITORS; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; IMMUNIZATION; IMMUNOSUPPRESSION;

EID: 84893851961     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.163     Document Type: Review

References (78)

1. Adler ED, Goldfinger JZ, Kalman J, Park ME, Meier DE. Palliative care in the treatment of advanced heart failure. Circulation 120(25), 2597-2606 (2009).
2. Costanzo MR, Mills RM, Wynne J. Characteristics of 'Stage D' heart failure: insights from the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE LM). Am. Heart J. 155(2), 339-347 (2008).
3. Rose EA, Gelijns AC, Moskowitz AJ et al. Long-term use of a left ventricular assist device for end-stage heart failure. N. Engl. J. Med. 345(20), 1435-1443 (2001).
4. Miller LW, Pagani FD, Russell SD et al. Use of a continuous-flow device in patients awaiting heart transplantation. N. Engl. J. Med. 357(9), 885-896 (2007). (Pubitemid 47347322)
5. Aaronson KD, Slaughter MS, Miller LW et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation 125(25), 3191-3200 (2012).
6. Stehlik J, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report-2011. J. Heart Lung Transplant. 30(10), 1078-1094 (2011).
7. Cheung A, Menkis AH. Cyclosporine heart transplantation. Transplant. Proc. 30(5), 1881-1884 (1998). (Pubitemid 28399356)
8. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu. Rev. Immunol. 27(1), 591-619 (2009).
9. Turka LA, Linsley PS, Lin H et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl Acad. Sci. 89(22), 11102-11105 (1992).
10. Lindenfeld J, Miller GG, Shakar SF et al. Drug therapy in the heart transplant recipient: part II. Immunosuppressive drugs. Circulation 110(25), 3858-3865 (2004). (Pubitemid 40023985)
11. Reed EF, Demetris AJ, Hammond E et al. Acute antibody-mediated rejection of cardiac transplants. J. Heart Lung Transplant. 25(2), 153-159 (2006). (Pubitemid 43156365)
12. Stastny P, Salvador I-M, Lavingia B. Evaluation of the highly sensitized transplant recipient. Pediatr. Nephrol. 26(11), 1927-1935 (2011).
13. Goulmy E. Minor histocompatibility antigens: from transplantation problems to therapy of cancer. Hum. Immunol. 67(6), 433-438 (2006). (Pubitemid 43765612)
14. Cecka JM. Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am. J. Transplant. 10(1), 26-29 (2010).
15. Kobashigawa J, Mehra M, West L et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J. Heart Lung Transplant. 28(3), 213-225 (2009).
16. Stehlik J, Islam N, Hurst D et al. Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. J. Heart Lung Transplant. 28(11), 1129-1134 (2009).
17. Tinckam KJ, Chandraker A. Mechanisms and role of HLA and non-HLA alloantibodies. Clin. J. Am Soc. Nephrol. 1(3), 404-414 (2006).
18. Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgartner WA, Conte JV. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann. Thorac. Surg. 84(5), 1556-1563 (2007). (Pubitemid 47588132)
19. Yousufuddin M, Haji S, Starling RC et al. Cardiac angiotensin II receptors as predictors of transplant coronary artery disease following heart transplantation. Eur. Heart J. 25(5), 377-385 (2004). (Pubitemid 38391519)
20. Kauke T, Kaczmarek I, Dick A et al. Anti-MICA antibodies are related to adverse outcome in heart transplant recipients. J. Heart Lung Transplant. 28(4), 305-311 (2009).
21. Uber PA, Mehra MR. Induction therapy in heart transplantation: is there a role? J. Heart Lung Transplant. 26(3), 205-209 (2007). (Pubitemid 46341883)
22. Emin A, Rogers CA, Thekkudan J, Bonser RS, Banner NR. Antithymocyte globulin induction therapy for adult heart transplantation: a UK national study. J. Heart Lung Transplant. 30(7), 770-777 (2011).
23. Teuteberg JJ, Shullo MA, Zomak R et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am. J. Transplant. 10(2), 382-388 (2010).
24. Hao WJ, Zong HT, Cui YS, Zhang Y. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis. Transplant. Proc. 44(10), 2955-2960 (2012).
25. Zhang R, Haverich A, Strüber M, Simon A, Bara C. Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin. J. Heart Lung Transplant. 27(6), 603-609 (2008). (Pubitemid 351711706)
26. Hershberger RE, Starling RC, Eisen HJ et al. Daclizumab to prevent rejection after cardiac transplantation. N. Engl. J. Med. 352(26), 2705-2713 (2005). (Pubitemid 41007825)
27. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am. J. Transplant. 4(2), 222-230 (2004). (Pubitemid 38248525)
28. Liu Y, Zhou P, Han M, Xue CB, Hu XP, Li C. Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis. Transplant. Proc. 42(5), 1667-1670 (2010).
29. Mattei MF, Redonnet M, Gandjbakhch I et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J. Heart Lung Transplant. 26(7), 693-699 (2007). (Pubitemid 47001715)
30. Charpentier B. An induction versus no-induction protocol in anticalcineurin-based immunosuppression using very low-dose steroids. Transplant. Proc. 33(4 Suppl. 1), S3-S10 (2001). (Pubitemid 32768719)
31. Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolatemofetil in heart transplant recipients. Transplantation 66(4), 507-515 (1998). (Pubitemid 28415379)
32. Baran DA, Zucker MJ, Arroyo LH et al. A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the Tacrolimus in Combination, Tacrolimus Alone Compared (TICTAC) trial. Circ. Heart Fail. 4(2), 129-137 (2011).
33. Kobashigawa JA. Strategies in immunosuppression after heart transplantation: is less better? Circ. Heart Fail. 4(2), 111-113 (2011).
34. Lindenfeld J, Miller GG, Shakar SF et al. Drug therapy in the heart transplant recipient: part I. Cardiac rejection and immunosuppressive drugs. Circulation 110(24), 3734-3740 (2004). (Pubitemid 39665265)
35. Kobashigawa JA, Miller LW, Russell SD et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am. J. Transplant. 6(6), 1377-1386 (2006). (Pubitemid 44030320)
36. Taylor DO, Barr ML, Radovancevic B et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J. Heart Lung Transplant. 18(4), 336-345 (1999). (Pubitemid 29205269)
37. Reichart B, Meiser B, Viganò M et al. European multicenter tacrolimus heart pilot study: three year follow-up. J. Heart Lung Transplant. 20(2), 249-250 (2001).
38. Pham MX, Teuteberg JJ, Kfoury AG et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N. Engl. J. Med. 362(20), 1890-1900 (2010).
39. Pham MX, Deng MC, Kfoury AG, Teuteberg JJ, Starling RC, Valantine H. Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the Invasive Monitoring Attenuation Through Gene Expression (IMAGE) trial. J. Heart Lung Transplant. 26(8), 808-814 (2007). (Pubitemid 47202072)
40. Kobashigawa J, Patel J, Kittleson M et al. Results of a randomized trial of AlloMap® vs heart biopsy in the 1st year after heart transplant: early invasive monitoring attenuation through gene expression trial. J. Heart Lung Transplant. 32(4 Suppl.), S203 (2013).
41. Stewart S, Winters GL, Fishbein MC et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transplant. 24(11), 1710-1720 (2005). (Pubitemid 41641841)
42. Ho EK, Vlad G, Vasilescu ER et al. Pre-and post-transplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum. Immunol. 72(1), 5-10 (2011).
43. Smith JD, Banner NR, Hamour IM et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am. J. Transplant. 11(2), 312-319 (2011).
44. Kittleson MM, Kobashigawa JA. Antibody-mediated rejection. Curr. Opin. Organ Transplant. 17(5), 551-557 (2012).
45. Arnaoutakis GJ, George TJ, Kilic A et al. Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: update in a modern cohort. J. Thorac. Cardiovasc. Surg. 142(5), 1236. e1231-1245.e1231 (2011).
46. Kobashigawa J, Crespo-Leiro MG, Ensminger SM et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J. Heart Lung Transplant. 30(3), 252-269 (2011).
47. Berry GJ, Angelini A, Burke MM et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J. Heart Lung Transplant. 30(6), 601-611 (2011).
48. Wu GW, Kobashigawa JA, Fishbein MC et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J. Heart Lung Transplant. 28(5), 417-422 (2009).
49. Patel JK, Kobashigawa JA. Improving survival during heart transplantation: diagnosis of antibody-mediated rejection and techniques for the prevention of graft injury. Future Cardiol. 8(4), 623-635 (2012).
50. Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 86(12), 1754-1761 (2008).
51. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. J. Heart Lung Transplant. 30(12), 1320-1326 (2011).
52. Kittleson MM, Patel JK, Moriguchi JD et al. Heart transplant recipients supported with extracorporeal membrane oxygenation: outcomes from a single-center experience. J. Heart Lung Transplant. 30(11), 1250-1256 (2011).
53. Stegall MD, Diwan T, Raghavaiah S et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am. J. Transplant. 11(11), 2405-2413 (2011).
54. Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333(10), 621-627 (1995).
55. Fang JC, Kinlay S, Beltrame J et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 359(9312), 1108-1113 (2002). (Pubitemid 34270735)
56. Kfoury AG, Hammond MEH, Snow GL et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J. Heart Lung Transplant. 28(8), 781-784 (2009).
57. Mehra MR, Crespo-Leiro MG, Dipchand A et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J. Heart Lung Transplant. 29(7), 717-727 (2010).
58. Kobashigawa JA, Tobis JM, Starling RC et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J. Am. Coll. Cardiol. 45(9), 1532-1537 (2005). (Pubitemid 40615630)
59. Keogh A, Richardson M, Ruygrok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 110(17), 2694-2700 (2004). (Pubitemid 39453021)
60. Morath C, Arns W, Schwenger V et al. Sirolimus in renal transplantation. Nephrol. Dial. Transplant. 22(Suppl. 8), viii61-viii65 (2007).
61. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349(14), 1315-1323 (2003). (Pubitemid 37186209)
62. Hill JA, Hummel M, Starling RC et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 84(11), 1436-1442 (2007). (Pubitemid 350294718)
63. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. 349(9), 847-858 (2003). (Pubitemid 37025404)
64. Eisen HJ, Kobashigawa J, Starling RC et al. Everolimus versus mycophenolatemofetil in heart transplantation: a randomized, multicenter trial. Am. J. Transplant. 13(5), 1203-1216 (2013).
65. Kobashigawa JA, Patel JK. Immunosuppression for heart transplantation: where are we now? Nat. Clin. Prac. Cardiovasc. Med. 3(4), 203-212 (2006).
66. Chin C, Hunt S, Robbins R, Hoppe R, Reitz B, Bernstein D. Long-term follow-up after total lymphoid irradiation in pediatric heart transplant recipients. J. Heart Lung Transplant. 21(6), 667-673 (2002). (Pubitemid 34626360)
67. Barr ML, Meiser BM, Eisen HJ et al. Photopheresis for the prevention of rejection in cardiac transplantation. N. Engl. J. Med. 339(24), 1744-1751 (1998). (Pubitemid 28555433)
68. Kirklin JK, Brown RN, Huang ST et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J. Heart Lung Transplant. 25(3), 283-288 (2006). (Pubitemid 43290657)
69. Kobashigawa JA. The future of heart transplantation. Am. J. Transplant. 12(11), 2875-2891 (2012).
70. Shah MR, Starling RC, Schwartz Longacre L, Mehra MR. Heart transplantation research in the next decade-a goal to achieving evidence-based outcomes: National Heart, Lung, and Blood Institute Working Group. J. Am. Coll. Cardiol. 59(14), 1263-1269 (2012).
71. Chin C, Chen G, Sequeria F et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J. Heart Lung Transplant. 30(2), 158-163 (2011).
72. Kransdorf EP, Kobashigawa JA. Genetic and genomic approaches to the detection of heart transplant rejection. Pers. Med. 9(7), 693-705 (2012).
73. Koestenbauer S, Stiegler P, Stadlbauer V et al. Myeloperoxidase and carbonyl proteins: promising markers for non-invasive monitoring of graft rejection after heart transplantation. J. Heart Lung Transplant. 29(12), 1352-1357 (2010).
74. Zelzer S, Stiegler P, Kapitan M et al. Myeloperoxidase as serum marker for detection of CMV infections and rejections in patients after liver or heart transplantation. Transplant. Immunol. 20(3), 121-126 (2009).
75. Yamani MH, Yang J, Masri CS et al. Acute cellular rejection following human heart transplantation is associated with increased expression of vitronectin receptor (integrin avb3). Am. J. Transplant. 2(2), 129-133 (2002). (Pubitemid 36306791)
76. Kobashigawa JA, Kiyosaki KK, Patel JK et al. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. J. Heart Lung Transplant. 29(5), 504-508 (2010).
77. Kingsley CI, Karim M, Bushell AR, Wood KJ. CD25+CD4+ regulatory T cells prevent graft rejectiosn: CTLA-4-and IL-10-dependent immunoregulation of alloresponses. J. Immunol. 168(3), 1080-1086 (2002). (Pubitemid 34094471)
78. Costanzo MR, Costanzo MR, Dipchand A et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J. Heart Lung Transplant. 29(8), 914-956 (2010).